ClinicalTrials.gg
RecruitingNCT07144176Updated Aug 28, 2025

PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers

A Phase 1 interventional study of DWJ1511 and DWC202501 in Healthy Subjects, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Study summary

PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers

Read the detailed description

This is an open-label, randomized, single-dose, two-treatment, two-period, crossover, phase 1 clinical trial conducted under fasting conditions to compare and evaluate the pharmacokinetics (PK) and safety of DWJ1511 and DWC202501. in healthy adult volunteers. Participants will receive both study drugs in separate periods, with a washout interval between administrations. The study aims to assess PK parameters and monitor safety through clinical evaluations and laboratory tests.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged ≥19 years and \<65 years at the time of screening
  • (BMI) between 18 and 30 kg/m² (BMI = weight [kg] / height [m]²)

Exclusion criteria

Exclusion Criteria:

  • Subjects who have participated in a bioequivalence study or any other clinical trial and have received an product within 6 months prior to the first administration.
  • Subjects who have donated whole blood within 8 weeks prior to the first administration, donated blood components within 2 weeks prior to the first administration, or received a blood transfusion within 4 weeks prior to the first administration.
  • Subjects with a history of gastrointestinal surgery that may affect drug absorption (appendectomy and hernia repair are not exclusionary).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    A(RT)

    30 Subjects, Cross-over, Single dose DWC202501 on period 1, Single dose of DWJ1511 on period 2

    Drug: DWJ1511 · Drug: DWC202501

  • Active comparator
    B(TR)

    30 Subjects, Cross-over, Single dose DWJ1511 on period 1, Single dose of DWC202501 on period 2

    Drug: DWJ1511 · Drug: DWC202501

Interventions

  • DrugDWJ1511

    Test drug: DWJ1511

  • DrugDWC202501

    Comparator: DWC202501

06

What researchers measure

Primary outcomes

  1. Area under the plasma drug concentration-time curve [AUCt]

    Area under the plasma drug concentration-time curve \[AUCt\] of DWJ1511 and DWC202501

    Time frame: 0-12 Hours

  2. Maximum plasma concentration [Cmax]

    Maximum plasma concentration \[Cmax\] of DWJ1511 and DWC202501

    Time frame: 0-12 Hours

Secondary outcomes

  1. Area under the plasma drug concentration-time curve from time 0 to infinity [AUCinf]

    Area under the plasma drug concentration-time curve from time 0 to infinity \[AUCinf\] of DWJ1511 and DWC202501

    Time frame: 0-12 Hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Sep 2025, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Aug 27, 2025
StartEst.
Sep 2025
Primary completionEst.
Sep 2025
CompletionEst.
Sep 2025
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07144176
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Sep 2025 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Aug 28, 2025

Study contacts

Kang
Contact
juspa@newyjh.com
82) 070-4665-9490

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion